MedTrace Logo

The Real-world Clinical Study of Azvudine Tablets in the Treatment of COVID-19

NCT06349655 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 32864

Last updated 2024-04-05

No results posted yet for this study

Summary

To establish a real-world clinical cohort and database of Azvudine in the treatment of SARS-CoV-2 infection, and to provide stable and reliable evidence for the clinical efficacy and safety evaluation of azvudine in the treatment of SARS-CoV-2 infection.

Conditions

Interventions

DRUG

Azvudine

Antiviral drug

DRUG

Paxlovid

Antiviral drug

Sponsors & Collaborators

  • Henan Provincial Chest Hospital

    collaborator OTHER

  • The Affiliated Infectious Disease Hospital of Zhengzhou University

    collaborator UNKNOWN

  • The Fifth People's Hospital of Anyang

    collaborator UNKNOWN

  • Shangqiu Municipal Hospital

    collaborator UNKNOWN

  • Nanyang Central Hospital

    collaborator OTHER

  • Luoyang Central Hospital

    collaborator OTHER

  • Guangshan County People's Hospital

    collaborator UNKNOWN

  • Fengqiu County People's Hospital

    collaborator UNKNOWN

  • The First Affiliated Hospital of Zhengzhou University

    lead OTHER

Principal Investigators

  • Zujiang Yu, Dr. · The First Affiliated Hospital of Zhengzhou University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-05
Primary Completion
2024-01-15
Completion
2024-03-10

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06349655 on ClinicalTrials.gov